Effect of Extracorporeal Shockwave Therapy on Gait Parameters in Patients With Planter Fascitis

March 12, 2024 updated by: Elham Mohammed Khairy Abd El Azeem El Naggar, Cairo University

Effect of Extracorporeal Shockwave Therapy on Gait Parameters in Patients With Plantar Fascitis

The purpose of this study is :

  • to determine the effect of extracorporeal shockwave on pain intensity in patients with plantar fasciitis.
  • to determine the effect of extracorporeal shockwave on foot function in patients with plantar fasciitis.
  • to determine the effect of extracorporeal shockwave on gait parameters in patients with plantar fasciitis

Study Overview

Detailed Description

Plantar fasciitis with an accompanying heel spur is very burdensome and difficult to treat disease. It most often arises as a result of degenerative changes of the proximal plantar fascia and the tissues surrounding the aponeurosis, occurring due to continuous irritation of the area and resulting micro-injuries. The main symptom of plantar fasciitis is pain in the heel area; this worsens over time, increasingly occurring upon loading and eventually, even at rest. Redness and swelling are also observed in the heel. The risk of the disease is increased by being overweight, working a job that requires long periods of standing, lifting heavy objects.

About 85% to 90% of patients do not need to undergo surgery, and 80% of patient do not experience pain relapse after conservative treatments. Minimally invasive treatments commonly used for treating PF are extracorporeal shockwave therapy (ESWT), corticosteroid (CS)injections, platelet-rich plasma (PRP) injections, botulinum toxin (BTX), acupuncture, dry needling and prolotherapy.

Conservative treatment options for PF include rest, weight loss, non-steroidal anti-inflammatory drugs, physical therapies (ultrasound therapy, low-energy, and laser therapy), plantar fascia and calf muscle strengthening and stretching exercises. If symptoms persist, second-option treatment is usually local corticosteroid injections. However, despite providing a good effect in terms of pain reduction, corticosteroids have proven to damage the fascial tissue, thus increasing the risk of further degeneration and eventual rupture. To avoid this complication, Extracorporeal shock wave therapy (ESWT) is a treatment recommendation for patients with chronic PF recalcitrant to other conservative treatment.

Extracorporeal shockwave therapy (ESWT) is a physical therapy that generates three-dimensional pressure pulses, lasting microseconds and reaching peek pressures of 35-120 MPa, and has effects depending on intensity, pulse cycle and shockwave (SW) modality. We have two modalities of SW therapy: focused shockwave (FSW) and radial shockwave (RSW). FSW is documented as a possible alternative to the surgical approach: it focuses on a small area (2 to 8 mm) and penetrates at a selected depth, having effects that depend on the energy delivered to the focal area; that is why it is important to know the energy flux density (EFD), which is considered the "dose" of SW administered.

RSW produces SW that are transmitted radially and do not have penetrating effects on tissue, acting superficially. They are frequently used in soft-tissue pathologies and, recently, also in plantar fasciitis. As this physical therapy is widely used for the treatment of plantar fasciitis. The mechanism of ESWT is not completely clear. However, it is speculated that ESWT may produce a reflexive analgesic effect by inducing excitability of the axon and destroying unmyelinated sensory fibers.

Due to the negligible side effects, which only relate to minor referred pain during ESWT sessions and minor hematoma, this therapy represents a safe, advantageous, and well-tolerated approach without surgical risks or severe complications. Therefore, the use of ESWT has gained increasing popularity for treating different musculoskeletal disorders. These encompass tendinopathies (both calcifying and non-calcifying), plantar fasciitis (PF), lateral epicondylitis ("tennis elbow"), greater trochanteric pain syndrome, bone nonunion fractures, and joint diseases including avascular necrosis.

The extracorporeal shock wave produces a treatment effect by passing through muscle and adipose tissue and releasing energy at the border of the bone due to the difference in impedance. Therefore, ESWT improves the clinical condition of the plantar fascia. Thus, the benefits of ESWT may be fundamentally more difficult to achieve in patients with pain throughout the entire plantar fascia when the ESWT target site is far from the enthesis of the calcaneus. Furthermore, the investigators speculate that the ESWT effect may be insufficient in patients with degeneration of the plantar fascia itself.

Study Type

Interventional

Enrollment (Estimated)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • - 52 female patient with chronic planter fasciitis.
  • Patient,s age will be (18 - 40) , all of them are diagnosed with planter fasciitis will be recruited for the study.
  • BMI will be (18 - 40 kg/m2).
  • Unilateral chronic planter fasciitis.
  • Symptoms of pf pain lasted more than 3 months.
  • Diagnosis of painful heel syndrome by clinical examination, with the following positive clinical signs:

    • Pain in the morning or after sitting a long time.
    • Local pain where the fascia attaches to the heel.
    • Increasing pain with extended walking or standing for more than 15 minutes.
    • History of 6 months of unsuccessful conservative treatment.
  • Therapy free period of at least 4 weeks before referral.

Exclusion Criteria:

Patients will exclude from this study if their pain due to:

  • Bilateral plantar fasciitis.
  • Dysfunction of foot or ankle (for example, instability).
  • Arthrosis or arthritis of the foot.
  • Infections or tumors of the lower extremity.
  • Neurological abnormalities, nerve entrapment (for example, tarsal tunnel syndrome).
  • Vascular abnormality (for example, severe varicosities, chronic ischemia).
  • Operative treatment of the heel spur.
  • Hemorrhagic disorders and anticoagulant therapy.
  • Pregnancy.
  • Diabetes.
  • Trauma.
  • previous surgery.
  • Inflammation disease.
  • Rheumatoid arthritis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group (A) treatment group
Group (A) will receive extracorporeal shockwave therapy and (Ultrasound, stretching and strengthening exercises)

Devices used to improve foot function pain and gait pattern

Patients will be placed in prone position, therapist locate the point of maximum tenderness. treatment area will be prepared with coupling gel to minimize the loss of shockwave therapy at the interface between applicator tip and skin. Each patient will receive 2000 impulses ,3 bar energy,15mm depth applicator at frequency (10 HZ) per session / week for 4 weeks

Devices used to improve foot function pain and gait pattern

Participants in the study group will be treated with 5 minutes of therapeutic ultrasound at a frequency of 1 MHz and continuous current at a pulse intensity of 1.8 W/cm2 (when the sensitivity level was too high and the procedure hurt the patient, the therapist reduced the intensity . 3 sessions /week for 4 weeks

Experimental: Group (B) traditional group
Group (B) will receive (Ultrasound, stretching and strengthening exercises)

Devices used to improve foot function pain and gait pattern

Participants in the study group will be treated with 5 minutes of therapeutic ultrasound at a frequency of 1 MHz and continuous current at a pulse intensity of 1.8 W/cm2 (when the sensitivity level was too high and the procedure hurt the patient, the therapist reduced the intensity . 3 sessions /week for 4 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stride length mean distance measured by (meter)
Time Frame: 4 weeks
stride length (one of gait parameters) that will be assessed by using Kinovea software.
4 weeks
stride time mean time measured by (second)
Time Frame: 4 weeks
stride time (other gait parameters) that will be assessed by using kinovea software
4 weeks
speed mean distance/ time measured by (meter/second)
Time Frame: 4 weeks
speed (other gait parameters) that will be assessed by using kinovea software.
4 weeks
cadence mean number of steps /times.
Time Frame: 4 weeks
cadence (other gait parameters) that will be assessed by using kionvea software.
4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pain intensity level.
Time Frame: 4 weeks
pain intensity will be assessed by visual analogue scale. 0 mean (no pain) that mean better outcomes to 10 that mean (unbearable pain) that mean worst outcomes.
4 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Foot function
Time Frame: 4 weeks
foot function will be assessed by foot function index. 0 mean (no pain or difficulty) that mean better outcomes to 10 (worst pain imaginable or so difficult it requires help) that mean worst outcomes.
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Amir M Saleh, Professor, Cairo University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 12, 2024

Primary Completion (Estimated)

September 1, 2024

Study Completion (Estimated)

March 30, 2025

Study Registration Dates

First Submitted

March 4, 2024

First Submitted That Met QC Criteria

March 12, 2024

First Posted (Actual)

March 15, 2024

Study Record Updates

Last Update Posted (Actual)

March 15, 2024

Last Update Submitted That Met QC Criteria

March 12, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • ESWT on planter fascitis

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Plantar Fascitis

Clinical Trials on Extracorporeal shockwave therapy

Subscribe